T-cell therapy is the most efficacious approach for many patients with relapsed/refractory multiple myeloma, but it currently comes with 2 periods ...
Limited proactive offering of video visits by oncology teams, especially for nonusers, reduced exposure and normalized ...
MSK researchers found that BRCA2 mutations lower the barrier for RB1 loss, causing CDK4/6 inhibitor resistance.
Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes ...
In this episode of Community Corner, Christopher H. Lieu, MD, professor of medicine at the University of Colorado Cancer ...
Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer ...
The pivotal MajesTEC-3 trial led to FDA approval of teclistamab-daratumumab for relapsed/refractory multiple myeloma after at ...
Co-primary efficacy in RAS G12–mutant PDAC included statistically significant OS and PFS gains assessed by blinded ...
Day-45 MRD clearance favored cema-cel over observation by an absolute 41.6% in the first 24 evaluable patients, satisfying ...
Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists. Lung cancer treatment has undergone a remarkable transformation ...
At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...
Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results